Steve Kirsch Home page
  • Home
  • About
Sign in Subscribe
By Steve Kirsch in fluvoxamine — Dec 26, 2020

How I would treat COVID-19

How I would treat COVID-19
Fluvoxamine showed a 90% risk reduction in death in the Together Phase 3 trial. Then NIH will ignore the result.

Please see my answer on Quora for the most up-to-date version of this article.

Better still see the article on the home page about COVID treatments.

Previous

An open letter to public health officials

Next

Thank you to the people who made it possible for CETF to be successful

You might also like...

The Fluvoxamine FAQ
fluvoxamine

The Fluvoxamine FAQ

How I recommend people treat COVID and the fascinating backstory of how fluvoxamine was discovered.
Read More
Steve Kirsch
The case for fluvoxamine for treating COVID-19
fluvoxamine

The case for fluvoxamine for treating COVID-19

A very short op-ed arguing for using fluvoxamine against COVID.
Read More
Steve Kirsch
The case for adding fluvoxamine to the NIH COVID Guidelines
fluvoxamine

The case for adding fluvoxamine to the NIH COVID Guidelines

We don't know why the NIH panel is ignoring fluvoxamine and we aren't allowed to find out.
Read More
Steve Kirsch
Fluvoxamine news articles and op-eds
fluvoxamine

Fluvoxamine news articles and op-eds

Most recent articles first. Note that some of these articles are inaccurate.
Read More
Steve Kirsch
Steve Kirsch Home page © 2023
Powered by Ghost